The first, as yet less informative, US indications point slightly upwards for the BioNTech share. Quotes around $ 121 are called after a NASDAQ closing price on Friday at $ 120 (+1.11 percent). With prices between $ 114.42 and $ 120.75, the volatility was again within limits after the two turbulent trading patterns on Monday and Tuesday last week. This was already evident on the two days before and the turnover on NASDAQ with biotech shares has also decreased.
A consolidation phase remains that the BioNTech share is currently going through. The fact that the share price does not fall below the important broad support zone around the previous all-time high of 115 dollars in this phase is to be assessed positively for the share of the Mainz-based company. At the $ 112.50 / 115.00 mark, a clear technical support line appears to be establishing itself. Tests of the upper end of this support zone were carried out on Thursday and Friday last week, but they did not expose the brand to any great stress.